|
1
|
Gastroenteropancreatic neuroendocrine tumours.
|
Lancet Oncol
|
2008
|
7.65
|
|
2
|
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
|
Lancet
|
2011
|
4.79
|
|
3
|
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
|
J Clin Oncol
|
2011
|
2.57
|
|
4
|
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.
|
Am J Surg Pathol
|
2010
|
2.56
|
|
5
|
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
|
J Natl Cancer Inst
|
2003
|
2.19
|
|
6
|
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
|
Clin Cancer Res
|
2007
|
2.16
|
|
7
|
Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.
|
Clin Cancer Res
|
2008
|
1.98
|
|
8
|
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
|
J Clin Oncol
|
2010
|
1.49
|
|
9
|
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
|
Cancer
|
2011
|
1.43
|
|
10
|
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
|
Endocr Relat Cancer
|
2007
|
1.42
|
|
11
|
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.
|
World J Surg
|
2002
|
1.35
|
|
12
|
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus).
|
Pancreas
|
2010
|
1.31
|
|
13
|
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas.
|
Mod Pathol
|
2008
|
1.30
|
|
14
|
Well-differentiated pancreatic nonfunctioning tumors/carcinoma.
|
Neuroendocrinology
|
2007
|
1.26
|
|
15
|
PET in the diagnosis of neuroendocrine tumors.
|
Ann N Y Acad Sci
|
2004
|
1.17
|
|
16
|
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.
|
Acta Oncol
|
2010
|
1.15
|
|
17
|
Chemical characterization of brominated flame retardants and identification of structurally representative compounds.
|
Environ Toxicol Chem
|
2006
|
1.12
|
|
18
|
The role of PET in localization of neuroendocrine and adrenocortical tumors.
|
Ann N Y Acad Sci
|
2002
|
1.09
|
|
19
|
ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors.
|
Neuroendocrinology
|
2010
|
1.07
|
|
20
|
Poorly-differentiated endocrine carcinomas of midgut and hindgut origin.
|
Neuroendocrinology
|
2007
|
1.06
|
|
21
|
Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors.
|
Neuroendocrinology
|
2009
|
1.03
|
|
22
|
Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management.
|
Med J Aust
|
2010
|
1.02
|
|
23
|
A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A.
|
Regul Pept
|
2004
|
0.97
|
|
24
|
Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity.
|
Exp Cell Res
|
2002
|
0.96
|
|
25
|
A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.
|
Clin Cancer Res
|
2007
|
0.94
|
|
26
|
Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.
|
PLoS One
|
2010
|
0.93
|
|
27
|
Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors.
|
Mod Pathol
|
2013
|
0.92
|
|
28
|
Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1.
|
J Clin Endocrinol Metab
|
2004
|
0.92
|
|
29
|
Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre.
|
Lung Cancer
|
2013
|
0.90
|
|
30
|
Effects of interferon alpha on the expression of p21cip1/waf1 and cell cycle distribution in carcinoid tumors.
|
Cancer Invest
|
2002
|
0.90
|
|
31
|
Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.
|
Med Oncol
|
2007
|
0.90
|
|
32
|
Octreoscan in patients with bronchial carcinoid tumours.
|
Clin Endocrinol (Oxf)
|
2003
|
0.89
|
|
33
|
Somatostatin analogs for the treatment of neuroendocrine tumors.
|
Cancer Metastasis Rev
|
2011
|
0.89
|
|
34
|
A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B.
|
Regul Pept
|
2005
|
0.88
|
|
35
|
Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.
|
Anticancer Res
|
2007
|
0.88
|
|
36
|
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
|
Anticancer Res
|
2010
|
0.88
|
|
37
|
ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.
|
Neuroendocrinology
|
2010
|
0.87
|
|
38
|
Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
|
Neuroendocrinology
|
2014
|
0.85
|
|
39
|
Cancer: antitumor effects of octreotide LAR, a somatostatin analog.
|
Nat Rev Endocrinol
|
2010
|
0.85
|
|
40
|
A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum.
|
Endocr Relat Cancer
|
2011
|
0.84
|
|
41
|
Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior.
|
Neuroendocrinology
|
2005
|
0.83
|
|
42
|
Gene expression in midgut carcinoid tumors: potential targets for immunotherapy.
|
Acta Oncol
|
2005
|
0.82
|
|
43
|
Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report.
|
Digestion
|
2008
|
0.82
|
|
44
|
Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.
|
Therap Adv Gastroenterol
|
2013
|
0.82
|
|
45
|
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
|
Neuroendocrinology
|
2015
|
0.81
|
|
46
|
Expression of tyrosine kinase receptors in lung carcinoids.
|
Tumour Biol
|
2006
|
0.80
|
|
47
|
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.
|
Med Oncol
|
2002
|
0.80
|
|
48
|
Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET).
|
Ann N Y Acad Sci
|
2006
|
0.79
|
|
49
|
Severe systemic vasoconstriction starting with acute limb ischemia leading to death in a patient with well-differentiated pulmonary neuroendocrine carcinoma: a new paraneoplastic syndrome?
|
Acta Oncol
|
2011
|
0.79
|
|
50
|
Expression and function of vinculin in neuroendocrine tumors.
|
Tumour Biol
|
2007
|
0.79
|
|
51
|
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.
|
Acta Oncol
|
2009
|
0.79
|
|
52
|
CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.
|
Cancer Immunol Immunother
|
2007
|
0.79
|
|
53
|
In situ RNA-RNA hybridisation of phospholipase C beta 3 shows lack of expression in neuroendocrine tumours.
|
Anticancer Res
|
2003
|
0.78
|
|
54
|
Neuroendocrine tumors: recent progress in diagnosis and treatment.
|
Endocr Relat Cancer
|
2011
|
0.78
|
|
55
|
Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.
|
Med Oncol
|
2004
|
0.78
|
|
56
|
Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
|
Cancer Chemother Biol Response Modif
|
2003
|
0.78
|
|
57
|
Neuroendocrine tumor biomarkers: current status and perspectives.
|
Neuroendocrinology
|
2014
|
0.78
|
|
58
|
Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.
|
Virchows Arch
|
2006
|
0.78
|
|
59
|
Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
|
Med Oncol
|
2004
|
0.78
|
|
60
|
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
|
J Endocrinol Invest
|
2014
|
0.78
|
|
61
|
Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors.
|
Med Oncol
|
2003
|
0.77
|
|
62
|
The cytotoxic effect of emetine and CGP-74514A studied with the hollow fiber model and ArrayScan assay in neuroendocrine tumors in vitro.
|
Anticancer Agents Med Chem
|
2012
|
0.77
|
|
63
|
Malignant neuroendocrine tumors.
|
Cancer Chemother Biol Response Modif
|
2002
|
0.77
|
|
64
|
Neuroendocrine tumours.
|
Cancer Chemother Biol Response Modif
|
2005
|
0.77
|
|
65
|
Gastrin-releasing-peptide in neuroendorine tumours.
|
Acta Oncol
|
2006
|
0.77
|
|
66
|
Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
|
Cancer Chemother Pharmacol
|
2009
|
0.77
|
|
67
|
PET-Guided Surgery - High Correlation between Positron Emission Tomography with 11C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours.
|
Cancers (Basel)
|
2012
|
0.75
|
|
68
|
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors.
|
J Clin Oncol
|
2004
|
0.75
|
|
69
|
Molecular imaging in diagnosis of neuroendocrine tumours.
|
Lancet Oncol
|
2006
|
0.75
|
|
70
|
Gastric carcinoid in a patient infected with Helicobacter pylori: a new entity?
|
World J Gastroenterol
|
2011
|
0.75
|
|
71
|
The history and development of the gastroenteropancreatic endocrine axis.
|
Endocrinol Metab Clin North Am
|
2010
|
0.75
|
|
72
|
[Neuroendocrine tumors--new diagnostics and treatment].
|
Ugeskr Laeger
|
2010
|
0.75
|
|
73
|
Efficient human interferon-alpha gene transfer to neuroendocrine tumor cells with long-term and stable expression.
|
Neuroendocrinology
|
2006
|
0.75
|
|
74
|
[Lung carcinoids--not so benign as earlier believed].
|
Lakartidningen
|
2006
|
0.75
|
|
75
|
Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
|
Acta Oncol
|
2010
|
0.75
|
|
76
|
Selective internal radiation therapy in patients with carcinoid liver metastases.
|
Acta Oncol
|
2008
|
0.75
|